Studying Biomarkers in Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on E1302 Trial
Condition: Head and Neck Cancer
MeSH terms: Head and Neck Neoplasms
Study type: Observational

Summary: 
      RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory
      may help doctors learn more about changes that occur in DNA and identify biomarkers related
      to cancer. It may also help doctors predict how patients will respond to treatment.

      PURPOSE: This laboratory study is looking at biomarkers in samples from patients with
      recurrent or metastatic head and neck cancer treated on ECOG-E1302 trial.
    

Detailed description: 
      OBJECTIVES:

        -  To evaluate the frequency of ATP-binding cassette, sub-family G (WHITE), member 2
           (ABCG2), met proto-oncogene (hepatocyte growth factor receptor) (c-MET), and v-Ki-ras2
           Kirsten rat sarcoma viral oncogene homolog (K-ras) polymorphisms or mutations in this
           study population and the predictiveness of these polymorphisms on survival, time to
           progression, response rate, and toxicities.

      OUTLINE: Archived tumor tissue and peripheral blood mononuclear cells are analyzed for the
      frequency of ABCG2, c-MET, and K-ras polymorphisms or mutations by polymerase chain reaction
      (PCR). Results are then correlated with patients' clinical outcomes and toxicity.
    

Intervention name(s): mutation analysis; polymerase chain reaction; polymorphism analysis; laboratory biomarker analysis
Intervention type(s): Genetic; Genetic; Genetic; Other
Observational model: Other
Time perspective: Other
Sampling method: Non-Probability Sample
Study population: 
        Samples from patients accrued to E1302 from which specimens were submitted for research.
      
Keywords: recurrent squamous cell carcinoma of the hypopharynx; stage IV squamous cell carcinoma of the hypopharynx; recurrent squamous cell carcinoma of the larynx; stage IVA squamous cell carcinoma of the larynx; stage IVB squamous cell carcinoma of the larynx; stage IVC squamous cell carcinoma of the larynx; recurrent squamous cell carcinoma of the lip and oral cavity; stage IVA squamous cell carcinoma of the lip and oral cavity; stage IVB squamous cell carcinoma of the lip and oral cavity; stage IVC squamous cell carcinoma of the lip and oral cavity; recurrent metastatic squamous neck cancer with occult primary; recurrent squamous cell carcinoma of the nasopharynx; stage IV squamous cell carcinoma of the nasopharynx; recurrent squamous cell carcinoma of the oropharynx; stage IVA squamous cell carcinoma of the oropharynx; stage IVB squamous cell carcinoma of the oropharynx; stage IVC squamous cell carcinoma of the oropharynx; recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity; stage IVA squamous cell carcinoma of the paranasal sinus and nasal cavity; stage IVB squamous cell carcinoma of the paranasal sinus and nasal cavity; stage IVC squamous cell carcinoma of the paranasal sinus and nasal cavity; recurrent salivary gland cancer; stage IVA salivary gland cancer; stage IVB salivary gland cancer; stage IVC salivary gland cancer